Inotersen · Tegsedi

RNA / oligonucleotide

WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Transthyretin Amyloidosis with Polyneuropathy (FDA, approved 2018-10-05)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2025-02-14. The applicants told the FDA the products were no longer marketed and asked for the approvals to be withdrawn. Approval is withdrawn as of February 14, 2025. Approvals outside the US are listed below. The trials below are the product's evidence history.

Also approved (1)
EU
  • Stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR)
Product first approved 2018pharmaceuticalmanufacturer.media

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Other / comorbidity
NCT02175004 · Ionis Pharmaceuticals, Inc.
2014-06-26 – 2021-01-07 · FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
What this study did
Phase 2/3 (1)
Other / comorbidity
Phase 2 (2)
Other / comorbidity
NCT03702829 · Brigham and Women's Hospital
2019-02-28 – 2022-01-15 · Amyloidosis
What this study did
NCT02627820 · Brigham and Women's Hospital
2016-01 – 2018-12 · Amyloidosis
What this study did
Phase 4 (1)
Other / comorbidity
NCT04306510 · Akcea Therapeutics
2021-01-21 – 2024-03-20 · Hereditary Transthyretin Amyloidosis With Polyneuropthy
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT04136184 · Ionis Pharmaceuticals, Inc.
2019-12-11 – 2023-07-12 · Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: US approval withdrawn. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Inotersen (Tegsedi): this drugUS approval withdrawnRNA / oligonucleotideTransthyretin (TTR)Reliable signalNo reviewed efficacy summary in this indication
Acoramidis (Attruby)
Approved(overall)
Small moleculeTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)ApprovedRNA / oligonucleotideTransthyretin (TTR)Weak signalNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602)
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43)
Cliramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Nexiguran Ziclumeran
Phase 3(overall)
Gene therapy / editingTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 February 2025WithdrawalFDA withdrew approval of Tegsedi (NDA 211172) at the holder's request
US, FDA · FDA · Source ↗